Interaction Checker

Interacciones de Pasireotida

Pasireotida (Signifor, Signifor LAR) tiene 136 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 135; leves: 1; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones moderadas (135)

  • AcebutololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • AlfuzosinaalfabloqueanteModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • AmiodaronaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Amitriptilinaantidepresivo tricíclicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Anagrelidafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • AsenapinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • AtenololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Azelastina y fluticasonaantihistamínicoModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Azitromicinaantibiótico macrólidoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • BeclometasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • BetaxololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • BisoprololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Brimonidina y timololagonista alfa-adrenérgicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Bromocriptinaagonista de la dopaminaModerada

    Bromocriptine: Consider bromocriptine dose reduction. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • BudesonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • CarvedilolbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    Cyclosporine: Consider additional monitoring. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • CitalopramISRSModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • ClobetasolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • CloroquinaantipalúdicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • ClorpromazinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • ClozapinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • DeflazacortcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Deutetrabenazinainhibidor de VMAT2Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • DexametasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • DisopiramidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • DofetilidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Dorzolamida y timololinhibidor de la anhidrasa carbónicaModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • DronedaronaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Droperidolantagonista de la dopaminaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • EscitalopramISRSModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • EsmololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • FingolimodinmunosupresorModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • FlecainidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • FludrocortisonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • FluoxetinaISRSModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • FluticasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Granisetrónfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • HalobetasolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • HaloperidolantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • HidrocortisonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • HidroxizinaantihistamínicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • IbutilidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • IloperidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Ketoconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • LabetalolbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • LevofloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Levotiroxinahormona tiroideaModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Liotironinahormona tiroideaModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Loperamidafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • MetadonaopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • MetilprednisolonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Metimazolfármaco antitiroideoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

  • MetoprololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • MoxifloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • NadololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • NebivololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Nilotinibfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • OfloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Ondansetrónfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • PaliperidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Pentamidinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • PimavanserinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • PimozidaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • PindololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Pitolisantfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • PrednisolonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • ProcainamidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • PrometazinaantihistamínicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Prometazina y codeínaopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Propiltiouracilofármaco antitiroideoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

  • PropranololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • QuinidinaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • QuininaantipalúdicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • RisperidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • SolifenacinaanticolinérgicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • SotalolbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Teriparatidahormona tiroideaModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Tetrabenazinainhibidor de VMAT2Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • TimololbetabloqueanteModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • TioridazinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • TolterodinaanticolinérgicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Toremifenomodulador selectivo de los receptores de estrógenosModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • TramadolopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • TrazodonaantidepresivoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • TriamcinolonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Valbenazinainhibidor de VMAT2Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Vardenafiloinhibidor de la PDE5Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • VenlafaxinaIRSNModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (etiqueta de Pasireotida, Advertencias y precauciones)

  • Voriconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

  • ZiprasidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etiqueta de Pasireotida, Interacciones medicamentosas)

Menciones leves (1)

  • AlcoholAlcoholLeve

    In some reported post-marketing cases of ketoacidosis in patients taking SIGNIFOR LAR, factors predisposing to ketoacidosis such as acute illness, infection, pancreatic disorders (e.g., pancreatic malignancy or pancreatic surgery), and alcohol abuse were present. (etiqueta de Pasireotida, Advertencias y precauciones)

Compruebe Pasireotida frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.